PBMC Culture & Immunology Assays — Serum Selection Guide
Peripheral blood mononuclear cells (PBMCs) are the primary cell system for human immunology research — T cell, B cell, NK cell, monocyte and dendritic cell biology. Used in vaccine immunogenicity studies, clinical trial immunomonitoring, CAR-T potency testing, ADCC/CDC assays and infectious disease research. Serum quality is the single most variable factor in PBMC assay reproducibility.
Human Serum AB HI — Gold Standard
Preferred for vaccine immunogenicity ELISpot and OPA. AB type — no anti-A/B agglutination. Heat inactivated — no complement interference. Species-matched human matrix reflects in vivo immune conditions.
FBS Very Low Endotoxin ≤1 EU/mL
When FBS is required: VLE grade eliminates TLR4-mediated monocyte activation — the primary cause of high background in ELISpot and multiplex cytokine assays. Single lot reservation for full campaign.
Human Serum AB OTC — OPA
Opsonophagocytosis assays require active human complement + human IgG together in the correct species context. Only Human Serum AB OTC native provides both — bovine serum cannot replicate human opsonisation.
BSA Low Endotoxin for ELISA
1–3% BSA Low Endotoxin ≤5 EU/mg as ELISA blocking buffer. Standard BSA contains variable endotoxin that activates cells in PBMC co-culture detection systems — low endotoxin grade is not optional.
Human Serum AB vs FBS — which to use for PBMC assays
The choice depends on whether the assay requires physiological relevance to the human immune environment or whether cost-effective endotoxin-controlled culture is sufficient.
Human Serum AB HI is preferred when: the assay measures vaccine immunogenicity or clinical immune responses where species-matched matrix matters; bovine xenogenic proteins could stimulate non-specific immune responses; regulatory or clinical trial submissions require a human matrix; or opsonophagocytosis (OPA) assays require active human complement and IgG together.
FBS Very Low Endotoxin is appropriate for routine research PBMC culture, Granzyme B/Perforin ELISpot, multiplex cytokine assays, T cell proliferation, and Treg suppression assays — where cost is a constraint and the assay readout is not sensitive to bovine xenogenic background, provided endotoxin is controlled at ≤1 EU/mL.
Overnight rest before stimulation: PBMC isolation by Ficoll causes mechanical stress that primes cells for non-specific cytokine release. A 16–24 hour rest at 37°C in VLE FBS or Human Serum AB HI before stimulation consistently reduces ELISpot background spot counts. Do not change serum between rest and stimulation — serum change introduces variability.
Cryopreservation: 90% FBS VLE or 90% Human Serum AB HI + 10% DMSO. VLE/HI grade mandatory — endotoxin in standard FBS activates cells during freeze-thaw, reducing post-thaw viability and functional recovery.
Recommended products
- Human Serum AB HI — ELISpot, PBMC assays — first choice
- Human Serum AB OTC — OPA complement + opsonin source
- Human Serum AB OTC Male — NK & T cell expansion
- FBS Very Low Endotoxin ≤1 EU/mL — ELISpot, cytokine assays
- FBS Ultra Low IgG <5 µg/mL — NK cell ADCC, CD107a
- BSA Low Endotoxin — ELISA blocking, flow cytometry buffer
PBMC Assay Types — Serum Requirements
| Assay Type | Recommended Serum | Why | Concentration |
|---|---|---|---|
| IFN-γ ELISpot (vaccine immunogenicity) | Human Serum AB HI or FBS VLE ≤1 EU/mL | Endotoxin activates monocytes via TLR4 → non-specific IFN-γ spots. Human serum preferred — species-matched matrix reflects in vivo conditions. | 5–10% |
| Granzyme B / Perforin ELISpot (CTL) | FBS VLE ≤1 EU/mL | Endotoxin activates NK cells non-specifically via monocyte IL-12 → background degranulation spots independent of antigen-specific stimulation. | 5–10% |
| Multiplex cytokine assay (Luminex, MSD) | FBS VLE ≤1 EU/mL | Endotoxin drives monocyte IL-6, TNF-α, IL-1β → elevates baseline cytokine levels in unstimulated controls, masking treatment effects. | 5–10% |
| T cell proliferation (CFSE, Ki67) | FBS VLE ≤1 EU/mL or Human Serum AB HI | Endotoxin causes bystander T cell activation → inflates background proliferation in unstimulated wells. | 5–10% |
| NK cell cytotoxicity / ADCC (CD107a) | FBS VLE ≤1 EU/mL + FBS Ultra Low IgG for ADCC | Endotoxin activates NK cells non-specifically. Bovine IgG in standard FBS occupies FcγRIII (CD16) → reduces ADCC signal. | 5–10% |
| Monocyte / DC maturation | FBS VLE ≤1 EU/mL | Monocytes are exquisitely LPS-sensitive — endotoxin in standard FBS drives spontaneous CD80/CD86 upregulation independent of experimental stimuli. | 5–10% differentiation; serum-free during stimulation |
| Opsonophagocytosis (OPA) | Human Serum AB OTC native | Requires active human complement + human IgG in the human Fc receptor pathway together — bovine serum cannot replicate this. | 10–25% as complement/opsonin source |
| Treg suppression assay | FBS VLE ≤1 EU/mL | Endotoxin activates effector T cells → impairs Treg suppressive function measurement and accurate Treg:Teff ratio determination. | 5–10% |
Human Serum AB HI vs FBS Very Low Endotoxin — Comparison
| Criterion | FBS Very Low Endotoxin | Human Serum AB HI |
|---|---|---|
| Species match | Bovine — xenogenic matrix | Human — physiological match for human immune cells |
| Endotoxin | ≤1 EU/mL — controlled | Tested — low endotoxin lot selection |
| Complement | Present in non-HI — must use HI FBS for PBMC assays | Destroyed by 56°C/30 min — no spontaneous complement lysis |
| Cytokine background | Low with VLE grade | Lower — no bovine cytokine cross-reactivity in human assays |
| Vaccine immunogenicity ELISpot | Acceptable | Preferred — human matrix reflects in vivo immunological conditions |
| OPA assay | ✗ Not suitable | ✅ Native OTC: human complement + human IgG required |
| Cost | Lower | Higher — gold standard for clinical immunology |
| Donor variability | Lot-to-lot FBS variability | Pool variability — AB Male donors recommended for consistency |
PBMC Isolation — Serum at Each Step
| Step | Serum | Note |
|---|---|---|
| Ficoll density gradient | No serum — PBS or RPMI without serum | Serum in the Ficoll layer reduces separation efficiency — omit entirely |
| Wash steps | RPMI without serum or 0.5% BSA Low Endotoxin | Minimal protein — prevents premature cell activation during washing |
| Rest / recovery culture (2–24h) | FBS VLE ≤1 EU/mL or Human Serum AB HI at 5–10% | Overnight rest reduces isolation-induced activation — critical for low background ELISpot results |
| Stimulation & assay culture | Same serum as rest culture throughout | Do not change serum between rest and stimulation — introduces variability |
| Cryopreservation | 90% FBS VLE or 90% Human Serum AB HI + 10% DMSO | High serum concentration for cryoprotection. VLE/HI mandatory — standard FBS endotoxin activates cells during freeze-thaw |
BSA in PBMC-Based Immunology Assays
| Application | Product | Concentration | Function |
|---|---|---|---|
| ELISA blocking buffer (cytokine detection) | BSA Low Endotoxin ≤5 EU/mg | 1–3% in PBS-T | Prevents non-specific binding in cytokine ELISA — low endotoxin mandatory to avoid cell activation during blocking in co-culture detection formats |
| Flow cytometry staining buffer | BSA Low Endotoxin | 0.5–2% | Protein carrier in cell staining buffer — prevents non-specific antibody binding to Fc receptors on PBMCs |
| BCA / Bradford protein standard | BSA Low Endotoxin or BSA pH 5.2 | Calibration curve | Matrix-matched protein standard for BCA and Bradford assay. BSA pH 5.2 for pH-specific buffer compatibility in cytokine standard curve preparation. |
Frequently Asked Questions
Request Free Test Volumes for PBMC Assay Validation
Human Serum AB HI and OTC lot-specific endotoxin and viral testing data available on request. Free test samples for ELISpot and PBMC assay validation. Batch reservation for extended immunology campaigns.
Email: info@seamlessbio.de | +49 851 37932226
English 
Deutsch